Trading activity in Pfizer (PFE, Financial) options has been relatively modest, with a total of 95,000 contracts exchanged. The market is favoring calls over puts, resulting in a put/call ratio of 0.71, slightly below the usual 0.73 level.
The implied volatility (IV30) for Pfizer has increased by 2.19 points, reaching 29.12, which places it in the upper quartile. This level of volatility indicates an anticipated daily price movement of $0.41. Additionally, there is a noticeable steepening in the put-call skew, reflecting a heightened appetite for downside risk coverage.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 21 analysts, the average target price for Pfizer Inc (PFE, Financial) is $28.85 with a high estimate of $41.43 and a low estimate of $23.00. The average target implies an upside of 28.55% from the current price of $22.45. More detailed estimate data can be found on the Pfizer Inc (PFE) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, Pfizer Inc's (PFE, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Pfizer Inc (PFE, Financial) in one year is $27.27, suggesting a upside of 21.5% from the current price of $22.445. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Pfizer Inc (PFE) Summary page.
PFE Key Business Developments
Release Date: April 29, 2025
- Revenue: $13.7 billion, a decline of 6% operationally.
- Diluted EPS: $0.52 per share.
- Adjusted Diluted EPS: $0.92 per share.
- Adjusted Gross Margin: Approximately 81%.
- Total Adjusted Operating Expenses: $5.2 billion, a 12% decline operationally.
- Adjusted SI&A Expenses: Decreased 12% operationally.
- Adjusted R&D Expenses: Decreased 12% operationally.
- Dividend Returned to Shareholders: $2.4 billion.
- Internal R&D Investment: $2.2 billion.
- Full-Year 2025 Revenue Guidance: $61.0 to $64.0 billion.
- Full-Year 2025 Adjusted Diluted EPS Guidance: $2.80 to $3.00.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Pfizer Inc (PFE, Financial) reported strong financial performance in Q1 2025, with a focus on improving operating margins and cash flow.
- The company is advancing its R&D pipeline with multiple anticipated milestones, including regulatory decisions and Phase 3 readouts.
- Pfizer Inc (PFE) is expanding its commercial portfolio, with significant growth in key products like Vyndaqel, Nurtec, and Padcev.
- The company is committed to maintaining and growing its dividend, reinforcing its capital allocation strategy.
- Pfizer Inc (PFE) is leveraging digital tools and automation to achieve significant cost savings, aiming for $7.7 billion in savings by 2027.
Negative Points
- Pfizer Inc (PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design.
- The company faces challenges from competition in the market, particularly impacting the Vyndaqel family of products.
- There is uncertainty regarding potential tariffs, which could impact Pfizer Inc (PFE)'s financial performance and manufacturing strategy.
- The discontinuation of the danuglipron program in the obesity portfolio highlights challenges in R&D prioritization.
- Pfizer Inc (PFE) is navigating a complex global landscape with evolving trade and tariff policies, which could affect future operations.
